News and Trends 4 Oct 2022
Aeglea BioTherapeutics updates homocystinuria program
Aeglea BioTherapeutics, Inc. says dosing in the third cohort of the phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria is under way. Patients in this cohort…